CoChat
Sign Up
Cited by 51Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease

Open access
Salameh, Therese S, Rhea, Elizabeth M, Banks, William A, Hanson, Angela J·2016·Experimental Biology and Medicine
DOI 10.1177/1535370216660770PMC PMC4999626
Open this paper in CoChat — free account

Abstract

An increased risk for Alzheimer's disease is associated with dyslipidemia and insulin resistance. A separate literature shows the genetic risk for developing Alzheimer's disease is strongly correlated to the presence of the E4 isoform of the apolipoprotein E carrier protein. Understanding how apolipoprotein E carrier protein, lipids, amyloid β peptides, glucose, central nervous system insulin, and peripheral insulin interact with one another in Alzheimer's disease is an area of increasing interest. Here, we will review the evidence relating apolipoprotein E carrier protein, lipids, and insulin action to Alzheimer's disease and Aβ peptides and then propose mechanisms as to how these factors might interact with one another to impair cognition and promote Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1535370216660770

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 94

  1. [1]Lee EB. Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci 2011; 1243: 15–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. [2]Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. [3]Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dement 2011; 7: 280–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. [4]Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F, Pickering RM, Nicoll JAR, Holmes C, Hugon J, Boche D. Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease. J Pathol 2015; 235: 721–30. [DOI] [PubMed] [Google Scholar]
  5. [5]Ewers M, Frisoni GB, Teipel SJ, Grinberg LT, Amaro E, Jr, Heinsen H, Thompson PM, Hampel H. Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol 2011; 95: 535–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. [6]Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741–66. [DOI] [PubMed] [Google Scholar]
  7. [7]Demeester N, Castro G, Desrumaux C, De Geitere C, Fruchart JC, Santens P, Mulleners E, Engelborghs S, De Deyn PP, Vandekerckhove J, Rosseneu M, Labeur C. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J Lipid Res 2000; 41: 963–74. [PubMed] [Google Scholar]
  8. [8]Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009; 118: 103–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. [9]Erickson MA, Niehoff ML, Farr SA, Morley JE, Dillman LA, Lynch KM, Banks WA. Peripheral administration of antisense oligonucleotides targeting the amyloid-beta protein precursor reverses AbetaPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis 2012; 28: 951–60. [DOI] [PubMed] [Google Scholar]
  10. [11]Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287–303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. [13]Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein E knockout mice. Exp Neurol 2001; 169: 13–22. [DOI] [PubMed] [Google Scholar]
  12. [14]Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 2008; 67: 261–70. [DOI] [PubMed] [Google Scholar]
  13. [17]Mahley RW, Huang Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 2012; 76: 871–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. [18]Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JAR, Carare RO. Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ɛ4 allele. PLoS One 2012; 7: e41636–e41636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. [19]Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA. APOE, vascular pathology, and the AD brain. Neurology 2005; 65: 259–65. [DOI] [PubMed] [Google Scholar]
  16. [20]Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996; 148: 2083–95. [PMC free article] [PubMed] [Google Scholar]
  17. [21]Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. J Neurol Sci 2002; 203–204: 183–7. [DOI] [PubMed] [Google Scholar]
  18. [23]Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 2011; 286: 17536–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. [25]Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007; 298: 1300–11. [DOI] [PubMed] [Google Scholar]
  20. [26]Caselli RJ. Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy? Pediat Blood Cancer 2013; 10: 1739–42. [DOI] [PubMed] [Google Scholar]
  21. [27]Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. DiabMed 2011; 28: 1463–75. [DOI] [PubMed] [Google Scholar]
  22. [28]de la Monte SM. Relationships between diabetes and cognitive impairment. Endocrinol Metabol Clin North Am 2014; 43: 245–67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. [29]Blazquez E, Velázquez Sánchez E, Hurtado-Carneiro V, Ruiz Albusac JM. Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol 2014; 5: 1–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. [30]Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53: 1937–42. [DOI] [PubMed] [Google Scholar]
  25. [31]Newsholme P, Cruzat V, Arfuso F, Keane K. Nutrient regulation of insulin secretion and action. J Endocrinol 2014; 221: R105–20. [DOI] [PubMed] [Google Scholar]
  26. [32]Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006; 55(Suppl 2): S16–23. [DOI] [PubMed] [Google Scholar]
  27. [33]Goldberg EL, Dixit VD. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev 2015; 265: 63–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. [34]Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 14: 388–405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. [35]Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol Neurobiol 2013; 47: 145–71. [DOI] [PubMed] [Google Scholar]
  30. [36]Porte D, Jr., Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW. Obesity, diabetes and the central nervous system. Diabetologia 1998; 41: 863–81. [DOI] [PubMed] [Google Scholar]
  31. [37]Armbrecht HJ, Siddiqui AM, Green M, Farr SA, Kumar VB, Banks WA, Patrick P, Shah GN, Morley JE. Antisense against amyloid-beta protein precursor reverses memory deficits and alters gene expression in neurotropic and insulin-signaling pathways in SAMP8 mice. J Alzheimers Dis 2015; 46: 535–48. [DOI] [PubMed] [Google Scholar]
  32. [38]Freiherr J, Hallschmid M, Frey WH, 2nd, Brunner YF, Chapman CD, Holscher C, Craft S, De Felice FG, Benedict C. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013; 27: 505–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. [39]Banks WA, Jaspan JB, Kastin AJ. Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides 1997; 18: 1577–84. [DOI] [PubMed] [Google Scholar]
  34. [41]Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 2011; 225: 54–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. [42]Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63–80. [DOI] [PubMed] [Google Scholar]
  36. [43]Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 2004; 15: 955–9. [DOI] [PubMed] [Google Scholar]
  37. [44]Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. [45]Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D., Jr Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50: 164–8. [DOI] [PubMed] [Google Scholar]
  39. [46]Ghasemi R, Dargahi L, Haeri A, Moosavi M, Mohamed Z, Ahmadiani A. Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol Neurobiol 2013; 47: 1045–65. [DOI] [PubMed] [Google Scholar]
  40. [47]Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012; 64: 614–28. [DOI] [PubMed] [Google Scholar]
  41. [48]Meredith ME, Salameh T, Banks W. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J 2015; 17: 780–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. [49]Shiba K, Kageyama H, Takenoya F, Shioda S. Galanin-like peptide and the regulation of feeding behavior and energy metabolism. FEBS J 2010; 277: 5006–13. [DOI] [PubMed] [Google Scholar]
  43. [50]Shioda S, Kageyama H, Takenoya F, Shiba K. Galanin-like peptide: a key player in the homeostatic regulation of feeding and energy metabolism? Int J Obes 2011; 35: 619–28. [DOI] [PubMed] [Google Scholar]
  44. [51]Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJH, Andersen MR, Larsson HBW, Fahrenkrug J, Olesen J, Ashina M. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 2014; 137: 779–94. [DOI] [PubMed] [Google Scholar]
  45. [52]Kinhult J, Adner M, Uddman R, Cardell LO. Pituitary adenylate cyclase-activating polypeptide, effects in the human nose. Clin Exp Allerg 2003; 33: 942–9. [DOI] [PubMed] [Google Scholar]
  46. [53]Ueno H, Mizuta M, Shiiya T, Tsuchimochi W, Noma K, Nakashima N, Fujihara M, Nakazato M. Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes. Diab Care 2014; 37: 2024–7. [DOI] [PubMed] [Google Scholar]
  47. [54]Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol 2012; 69: 29–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. [55]Reger MA, Watson GS, Frey WH, 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006; 27: 451–8. [DOI] [PubMed] [Google Scholar]
  49. [56]Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70: 440–8. [DOI] [PubMed] [Google Scholar]
  50. [59]Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326–34. [DOI] [PubMed] [Google Scholar]
  51. [60]Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, Morley JE, Farr SA, Banks WA. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J Alzheimers Dis 2015; 47: 715–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. [61]Chen Y, Zhao Y, Dai C-l, Liang Z, Run X, Iqbal K, Liu F, Gong C-X. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 2014; 261: 610–9. [DOI] [PubMed] [Google Scholar]
  53. [62]Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Therapeut 2012; 136: 82–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. [63]Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010; 75: 764–70. [DOI] [PubMed] [Google Scholar]
  55. [64]Takeda S, Sato N, Uchio-Yamada K, Yu H, Moriguchi A, Rakugi H, Morishita R. Oral glucose loading modulates plasma beta-amyloid level in alzheimer's disease patients: potential diagnostic method for Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 34: 25–30. [DOI] [PubMed] [Google Scholar]
  56. [65]Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res 2010; 49: 159–70. [DOI] [PubMed] [Google Scholar]
  57. [66]Dumurgier J, Paquet C, Peoc'h K, Lapalus P, Mouton-Liger F, Benisty S, Chasseigneaux S, Chabriat H, Hugon J. CSF Abeta1-42 levels and glucose metabolism in Alzheimer's Disease. J Alzheimers Dis 2011; 27: 845–51. [DOI] [PubMed] [Google Scholar]
  58. [67]Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, 2nd, Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008; 13: 323–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. [68]Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapmana D, Watson GS, Cholerton B, Plymate SR, Arbuckle M, Craft S. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis 2013; 35: 789–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. [69]Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH, Hanson LR. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs 2014; 28: 1185–9. [DOI] [PubMed] [Google Scholar]
  61. [70]Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 2014; 44: 897–906. [DOI] [PubMed] [Google Scholar]
  62. [71]Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 2000; 903: 222–8. [DOI] [PubMed] [Google Scholar]
  63. [72]Hanson AJ, Bayer JL, Baker LD, Cholerton B, VanFossen B, Trittschuh E, Rissman RA, Donohue MC, Moghadam SH, Plymate SR, Craft S. Differential effects of meal challenges on cognition, metabolism, and biomarkers for apolipoprotein E varepsilon4 carriers and adults with mild cognitive impairment. J Alzheimers Dis 2015; 48: 205–18. [DOI] [PubMed] [Google Scholar]
  64. [73]Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol 2015; 38: 243–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. [74]Moon JH. Endocrine risk factors for cognitive impairment. Endocrinol Metab 2016; 31: 185–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. [75]Creegan R, Hunt W, McManus A, Rainey-Smith SR. Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer's disease pathology? Br J Nutr 2015; 113: 1499–517. [DOI] [PubMed] [Google Scholar]
  67. [77]Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004; 3: 579–87. [DOI] [PubMed] [Google Scholar]
  68. [78]Lim WL, Martins IJ, Martins RN. The involvement of lipids in Alzheimer's disease. J Genet Genom 2014; 41: 261–74. [DOI] [PubMed] [Google Scholar]
  69. [79]Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 2011; 12: 284–96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. [80]Rubin J, Berglund L. Apolipoprotein E and diets: a case of gene-nutrient interaction? Curr Opin Lipidol 2002; 13: 25–32. [DOI] [PubMed] [Google Scholar]
  71. [81]Kanoski SE, Meisel RL, Mullins AJ, Davidson TL. The effects of energy-rich diets on discrimination reversal learning and on BDNF in the hippocampus and prefrontal cortex of the rat. Behav Brain Res 2007; 182: 57–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. [82]Maesako M, Uemura M, Tashiro Y, Sasaki K, Watanabe K, Noda Y, Ueda K, Asada-Utsugi M, Kubota M, Okawa K, Ihara M, Shimohama S, Uemura K, Kinoshita A. High fat diet enhances beta-site cleavage of amyloid precursor protein (APP) via promoting beta-site APP cleaving enzyme 1/adaptor protein 2/clathrin complex formation. PLoS One 2015; 10: e0131199–e0131199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. [83]Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184–5. [DOI] [PubMed] [Google Scholar]
  74. [84]Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, Morley JE. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004; 53: 1253–60. [DOI] [PubMed] [Google Scholar]
  75. [85]Urayama A, Banks WA. Starvation and triglycerides reverse the obesity-induced impairment of insulin transport at the blood-brain barrier. Endocrinology 2008; 149: 3592–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. [86]Banks WA, Burney BO, Robinson SM. Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood-brain barrier. Peptides 2008; 29: 2061–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. [88]Durakoglugil M, Irving AJ, Harvey J. Leptin induces a novel form of NMDA receptor-dependent long-term depression. J Neurochem 2005; 95: 396–405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. [89]Shanley LJ, Irving AJ, Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosc 2001; 21: RC186–RC186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. [90]Jane MJ, William TH, David WF, Steven JG, George P, Thomas JM, John QT, Leslie MS, Ashford JW, Nikolaos T. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res 2014; 11: 165–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. [91]Johnston JM, Greco SJ, Hamzelou A, Ashford JW, Tezapsidis N. Repositioning leptin as a therapy for Alzheimer's disease. Therapy 2011; 8: 481–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. [92]Chang G-Q, Karatayev O, Davydova Z, Leibowitz SF. Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. Endocrinology 2004; 145: 3904–12. [DOI] [PubMed] [Google Scholar]
  82. [93]Wortley KE, Chang G-Q, Davydova Z, Leibowitz SF. Orexin gene expression is increased during states of hypertriglyceridemia. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1454–65. [DOI] [PubMed] [Google Scholar]
  83. [94]Welch CC, Kim E-M, Grace MK, Billington CJ, Levine AS. Palatability-induced hyperphagia increases hypothalamic dynorphin peptide and mRNA levels. Brain Res 1996; 721: 126–31. [DOI] [PubMed] [Google Scholar]
  84. [95]Oomura Y, Nakamura T, Sugimori M, Yamada Y. Effect of free fatty acid on the rat lateral hypothalamic neurons. Physiol Behav 1975; 14: 483–6. [DOI] [PubMed] [Google Scholar]
  85. [96]Shen L, Carey K, Wang DQH, Woods SC, Liu M. Food-entrained rhythmic expression of apolipoprotein E expression in the hypothalamus of rats. Brain Res 2009; 1273: 66–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. [97]Cordner ZA, Tamashiro KLK. Effects of high-fat diet exposure on learning & memory. Physiol Behav 2015; 152(Part B): 363–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. [98]Morley JE. The metabolic syndrome and aging. J Gerontol A Biol Sci Med Sci 2004; 59: M139–M42. [DOI] [PubMed] [Google Scholar]
  88. [100]Johnson LA, Zuloaga KL, Kugelman TL, Mader KS, Morré JT, Zuloaga DG, Weber S, Marzulla T, Mulford A, Button D, Lindner JR, Alkayed NJ, Stevens JF, Raber J. Amelioration of metabolic syndrome-associated cognitive impairments in mice via a reduction in dietary fat content or infusion of non-diabetic plasma. EBioMedicine 2015; 3: 26–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. [101]Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol 2013; 70: 972–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. [102]Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, Burke GL, Carlson MC. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005; 65: 1409–14. [DOI] [PubMed] [Google Scholar]
  91. [103]Barberger-Gateau P, Samieri C, Feart C, Plourde M. Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res 2011; 8: 479–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. [104]Henderson ST. High carbohydrate diets and Alzheimer's disease. Med Hypotheses 2004; 62: 689–700. [DOI] [PubMed] [Google Scholar]
  93. [105]Henderson ST, Poirier J. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study. BMC Med Genet 2011; 12: 137–137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. [106]Reger MA, Craft S. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today 2006; 42: 729–39. [DOI] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Salameh, T. S., Rhea, E. M., Banks, W. A., & Hanson, A. J.
Affiliations
University of Washington (US)
Corresponding author
Banks, William A
ORCID
Venue
Experimental Biology and Medicine
Publisher
Frontiers Media SA
Published
2016-07-28
Volume
241
Issue
15
Pages
1676-1683
ISSN
  • 0071-3384 (ISSN-L)
  • 1535-3702
  • 1535-3699
DOI
10.1177/1535370216660770
PMC
PMC4999626
OpenAlex
W2476631162
Cited by
51
References
12
Citations by year
2026: 3 · 2025: 9 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 6 · 2018: 3 · 2017: 4 · 2016: 1
FWCI
3.76
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Experimental Biology and Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institutes of Health
  • National Institute on Aging (T32AG000057, R01AG046619, P01AG001751, K23AG047978)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
insulin resistance, dyslipidemia, apolipoprotein E, APOE ε4, Alzheimer's disease, cognitive impairment, amyloid-beta, lipids, glucose metabolism
MeSH terms
Alzheimer Disease, Apolipoproteins E, Humans, Insulin Resistance, Amyloid beta-Peptides, Dyslipidemias, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review